| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
DC-Chol HCl does not have a specific biological target but functions as a cationic lipid for nucleic acid delivery. Its mechanism of action is based on its ability to form complexes (lipoplexes) with negatively charged nucleic acids (DNA, mRNA, siRNA) through electrostatic interactions. These complexes facilitate cellular uptake and endosomal escape, enabling the delivery of genetic material into cells for transfection and gene therapy applications. Its cationic nature and cholesterol backbone contribute to its membrane activity and transfection efficiency.
|
|---|---|
| ln Vitro |
In vitro, DC-Chol HCl is used as a transfection reagent for the delivery of nucleic acids into cells. It is used as a component of lipoplexes with DOPE for mRNA transfection in A549 cells without affecting cell viability. Its activity is concentration-dependent, and optimal transfection efficiency is typically achieved at specific lipid-to-nucleic acid ratios. The compound's ability to mediate efficient transfection makes it a valuable tool for gene delivery research and the development of non-viral gene therapy vectors.
|
| ln Vivo |
In vivo, DC-Chol HCl is used in preclinical studies for the development of non-viral gene delivery systems. Cationic liposomes containing DC-Chol have been investigated for the delivery of therapeutic nucleic acids, including mRNA and siRNA, to target tissues. The compound's in vivo behavior is formulation-dependent, and its effectiveness is influenced by the lipid composition, particle size, and route of administration. However, detailed in vivo efficacy data are limited in publicly available sources.
|
| Enzyme Assay |
The in vitro transfection assay for DC-Chol HCl typically involves the formation of lipoplexes by mixing the cationic lipid with nucleic acids (e.g., mRNA, plasmid DNA, siRNA) in a suitable buffer. The lipoplexes are then added to cells (e.g., A549 cells) in culture, and transfection efficiency is assessed by measuring the expression of a reporter gene (e.g., luciferase, GFP) or by qRT-PCR for the delivered nucleic acid. Cell viability is assessed using MTT or CellTiter-Glo assays to ensure that the lipoplex formulation is not cytotoxic. Positive controls (e.g., commercially available transfection reagents) and negative controls (cells alone) are included in each assay run.
|
| Cell Assay |
For in vitro cellular assays, cells (e.g., A549, HEK293) are seeded in 96-well or 24-well plates and treated with DC-Chol lipoplexes containing the nucleic acid of interest. Transfection efficiency is assessed by measuring reporter gene expression or target gene knockdown. Cell viability is assessed using MTT or CellTiter-Glo assays. For optimization studies, varying lipid-to-nucleic acid ratios and different formulations are tested. All experiments include appropriate controls (untransfected cells, cells treated with lipoplexes without nucleic acid) and are performed in triplicate.
|
| Animal Protocol |
For in vivo studies, DC-Chol-based liposomes or lipoplexes are typically administered to rodents via intravenous, intraperitoneal, or intratumoral injection. The liposomes may be used to deliver therapeutic nucleic acids (e.g., mRNA, siRNA, plasmid DNA) for gene therapy or vaccine applications. Biodistribution studies involve harvesting organs (liver, spleen, lung, kidney, tumor) and measuring nucleic acid or lipid content. Efficacy studies assess the therapeutic effect of the delivered nucleic acid. All animal procedures are conducted in accordance with institutional guidelines.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of DC-Chol HCl as a lipid component are typically characterized in the context of the liposomal formulation. When administered as liposomes, the lipid components are taken up by the reticuloendothelial system, primarily in the liver and spleen. The compound is metabolized by esterases and other enzymes, releasing cholesterol and the cationic headgroup. The half-life of liposomal lipids in circulation ranges from hours to days, depending on the formulation and surface modifications. The compound's distribution and elimination are influenced by its lipophilic nature and its incorporation into lipid bilayers.
|
| Toxicity/Toxicokinetics |
The toxicology of DC-Chol HCl is primarily evaluated in the context of liposomal formulations. As a cationic lipid, it can cause cytotoxicity at high concentrations due to membrane disruption. In cell culture, DC-Chol formulations show low cytotoxicity at optimal transfection concentrations. In vivo, cationic liposomes may cause mild inflammatory responses or RES saturation at high doses, but these effects are typically reversible. The compound is not genotoxic or carcinogenic. The safety profile supports its use in preclinical research for non-viral gene delivery.
|
| References | |
| Additional Infomation |
DC-Chol HCl is a cationic cholesterol derivative widely used in biomedical research for developing non-viral gene delivery systems. It has a molecular formula of C32H57ClN2O2 and a molecular weight of 537.3 g/mol. The compound is not approved for human therapeutic use and is intended for research purposes only. It is available as a high-purity research reagent (≥97%) for laboratory use. Its ability to mediate efficient transfection makes it a valuable tool for gene delivery, mRNA therapeutics, and vaccine research.
|
| Molecular Formula |
C32H56N2O2.HCL
|
|---|---|
| Molecular Weight |
537.26018
|
| Exact Mass |
536.411
|
| CAS # |
166023-21-8
|
| Related CAS # |
137056-72-5;166023-21-8 (HCl);
|
| PubChem CID |
16219102
|
| Appearance |
White to light yellow solid powder
|
| LogP |
8.69
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
37
|
| Complexity |
791
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)OC(=O)NCCN(C)C)C)C.Cl
|
| InChi Key |
ISXSJGHXHUZXNF-LXZPIJOJSA-N
|
| InChi Code |
InChI=1S/C32H56N2O2.ClH/c1-22(2)9-8-10-23(3)27-13-14-28-26-12-11-24-21-25(36-30(35)33-19-20-34(6)7)15-17-31(24,4)29(26)16-18-32(27,28)5;/h11,22-23,25-29H,8-10,12-21H2,1-7H3,(H,33,35);1H/t23-,25+,26+,27-,28+,29+,31+,32-;/m1./s1
|
| Chemical Name |
[(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] N-[2-(dimethylamino)ethyl]carbamate;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Ethanol : ~25 mg/mL (~46.53 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.65 mM) (saturation unknown) in 10% EtOH + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear EtOH stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.65 mM) (saturation unknown) in 10% EtOH + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear EtOH stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (4.65 mM) (saturation unknown) in 10% EtOH + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8613 mL | 9.3065 mL | 18.6130 mL | |
| 5 mM | 0.3723 mL | 1.8613 mL | 3.7226 mL | |
| 10 mM | 0.1861 mL | 0.9306 mL | 1.8613 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
